{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:34Z","timestamp":1790404834897,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A1A1A05020740"],"award-info":[{"award-number":["NRF-2018R1A1A1A05020740"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2019.00271","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T05:00:30Z","timestamp":1552971630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys"],"prefix":"10.3389","volume":"10","author":[{"given":"Sungjin","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hyun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Shik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.amjms.2016.08.015","article-title":"Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats.","volume":"352","author":"Chen","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/ndt\/gfp472","article-title":"Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.","volume":"25","author":"Chung","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00176","article-title":"The role of nitric oxide in the dysregulation of the urine concentration mechanism in diabetes mellitus.","volume":"3","author":"Cipriani","year":"2012","journal-title":"Front. Physiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2013.12.002","article-title":"Tissue-engineered kidney disease models.","volume":"6","author":"Desrochers","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00018-011-0858-4","article-title":"Molecular biology of water and salt regulation in the kidney.","volume":"69","author":"Esteva-Font","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/CIRCHEARTFAILURE.115.002259","article-title":"Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials.","volume":"8","author":"Felker","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"B9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/psp4.12178","article-title":"A quantitative systems physiology model of renal function and blood pressure regulation: model description.","volume":"6","author":"Hallow","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes.","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-50","article-title":"Delayed treatment with oleanolic acid attenuates tubulointerstitial fibrosis in chronic cyclosporine nephropathy through Nrf2\/HO-1 signaling.","volume":"12","author":"Hong","year":"2014","journal-title":"J. Transl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/en.2014-1257","article-title":"Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct.","volume":"155","author":"Hus-Citharel","year":"2014","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.kint.2016.12.005","article-title":"Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus.","volume":"91","author":"Khositseth","year":"2017","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"F760","DOI":"10.1152\/ajprenal.00369.2003","article-title":"Role of vasopressin in diabetes mellitus-induced changes in medullary transport proteins involved in urine concentration in Brattleboro rats.","volume":"286","author":"Kim","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"F474","DOI":"10.1152\/ajprenal.00477.2014","article-title":"Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney.","volume":"309","author":"Kim","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.krcp.2013.07.005","article-title":"Regulation of aquaporin-2 in the kidney: a molecular mechanism of body-water homeostasis.","volume":"32","author":"Kwon","year":"2013","journal-title":"Kidney Res. Clin. Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4093\/dmj.2017.0095","article-title":"Effect of empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on kidney and peripheral nerves in streptozotocin-induced diabetic rats.","volume":"42","author":"Lee","year":"2018","journal-title":"Diabetes Metab. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1681\/ASN.2014121200","article-title":"Defective store-operated calcium entry causes partial nephrogenic diabetes insipidus.","volume":"27","author":"Mamenko","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1055\/a-0815-4908","article-title":"Long-term treatment with empagliflozin attenuates renal damage in obese zucker rat.","author":"Manne","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF03351073","article-title":"Osteoporosis and risk of fracture in patients with diabetes: an update.","volume":"23","author":"Montagnani","year":"2011","journal-title":"Aging Clin. Exp. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s11255-012-0230-0","article-title":"Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III chronic kidney disease patients and healthy oldest old.","volume":"44","author":"Musso","year":"2012","journal-title":"Int. Urol. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1681\/ASN.2009111190","article-title":"Reciprocal regulation of aquaporin-2 abundance and degradation by protein kinase A and p38-MAP kinase.","volume":"21","author":"Nedvetsky","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1748-1716.2011.02260.x","article-title":"Opposing effects of NaCl restriction and carbohydrate loading on urine volume in diabetic rats.","volume":"202","author":"O\u2019Neill","year":"2011","journal-title":"Acta Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2215\/CJN.12391213","article-title":"Integrated control of Na transport along the nephron.","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.ajkd.2016.03.410","article-title":"No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?","volume":"68","author":"Perkins","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/VHRM.S111991","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.","volume":"12","author":"Reed","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"B30","doi-asserted-by":"publisher","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.","volume":"303","author":"Rieg","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5527\/wjn.v6.i1.1","article-title":"Hypertonicity: clinical entities, manifestations and treatment.","volume":"6","author":"Rondon-Berrios","year":"2017","journal-title":"World J. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method.","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1681\/ASN.2013111234","article-title":"A protein kinase A-independent pathway controlling aquaporin 2 trafficking as a possible cause for the syndrome of inappropriate antidiuresis associated with polycystic kidney disease 1 haploinsufficiency.","volume":"25","author":"Tamma","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus.","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone.","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome.","volume":"12","author":"van Bommel","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.bcp.2007.11.011","article-title":"Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.","volume":"75","author":"Veeraveedu","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2019.00271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T05:00:32Z","timestamp":1552971632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2019.00271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":41,"alternative-id":["10.3389\/fphys.2019.00271"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2019.00271","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"article-number":"271"}}